Yet another refusal on the part of the PTO to follow Federal Circuit guidelines spells more headaches for biotechnology.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
34 USPQ2d (BNA) 1210 (Fed. Cir. 1995).
41 USPQ2d 1172(1996).
226 USPQ (BNA) 359 (Fed. Cir. 1985).
Id. at 360.
See Amgen Inc. v. Chugai Pharmaceutical Co., 18 USPQ2d (BNA) 1016 (Fed. Cir. 1991) (“obviousness under §103 is a question of law”).
The Gillette Co. v. S.C. Johnson & Sons, Inc., 16 USPQ2d (BNA) 1923 (Fed. Cir. 1990).
In re Dillon, 16 USPQ2d (BNA) 1897 (1990).
34 USPQ2d(BNA) at 1215.
US Patent No. 4,666,829.
Glover, D.M. (ed). 1985. Constructing and screening cDNA libraries in Igt10 and Igt11, p.4978 in DNA Cloning: A Practical Approach, Vol. 1, IRL Press, Washington, DC.
Id.
Id. at 1176.
Id.
Id.
35 USC §103(a) (1996).
Amgen, Inc. v. Chugai Pharmaceutical Co., 18 USPQ2d (BNA) 1016 (Fed. Cir. 1991).
In re Deuel, 34 USPQ2d (BNA) 1210 (Fed. Cir. 1995).
Cf. Feist Publishings, Inc. v. Rural Telephone Services Co., 111 S.Ct. 1282, 18 USPQ2d 1275 (1991) (rejecting the “sweat of the brow” argument as a basis for a copyright).
Id.
S. Rep. No. 1979, 82nd Gong., 2nd Sess. 1952. Revision notes.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Chahine, K. Patenting DNA: Just when you thought it was safe. Nat Biotechnol 15, 586–587 (1997). https://doi.org/10.1038/nbt0697-586
Issue date:
DOI: https://doi.org/10.1038/nbt0697-586